India, April 28 -- Shares of Portage Biotech Inc. (PRTG) gained over 22% on Monday morning after the clinical-stage immuno-oncology company reported confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.
PRTG is currently trading at $10.38, up $1.93 or 22.84%, on the Nasdaq. The stock opened its trading at $8.45 after closing Friday at $11.31. The stock has traded between $2.10 and $23.01 in the past 52-week period.
The new data in a murine mesothelioma model demonstrated single agent activity for PORT-7 that was superior to treatment with single agent anti-PD1 antibody.
Moreover, the combination of PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone.
google...